Single-Cell Center, CAS Key Laboratory of Biofuels, Shandong Key Laboratory of Energy Genetics, Shandong Energy Institute, Qingdao Institute of Bioenergy and Bioprocess Technology, Chinese Academy of Sciences, Qingdao, Shandong, 266101, China
Auto-generated profile, based on publicly available information
Anle Ge
Single-Cell Center, CAS Key Laboratory of Biofuels, Shandong Key Laboratory of Energy Genetics, Shandong Energy Institute, Qingdao Institute of Bioenergy and Bioprocess Technology, Chinese Academy of Sciences, Qingdao, Shandong, 266101, China
Heterogeneous droplet array composites of hybrid biochemical/mechanical cues for high-throughput screening of cellular behaviors to various combinations of morphogens and matrix stiffness.
Accurately predicting the temporal and spatial distribution of intraocular drugs to enhance anti-glaucoma treatment efficacy remains a significant challenge in clinical ophthalmology. Developing more precise numerical models of intraocular drug transport holds substantial clinical value. This study establishes a model of intraocular drug transport, which includes the trabecular meshwork (TM), collector channels (CC), and uveoscleral outflow pathway, and analyzes the parameters affecting aqueous humor (AH) outflow and the impact of the uveoscleral pathway on drug transport. Results indicate that the uveoscleral pathway influences AH outflow, with its porous media significantly impeding drug clearance, leading to drug accumulation in the anterior chamber and higher concentrations in the TM. A reduction in TM porosity or the number of CC hinders drug transport to varying extents, increasing peak drug concentration at TM targets by 11.27% and 12.8%, respectively. Furthermore, neglecting the uveoscleral pathway may result in an 10.93% underestimation of TM drug concentration. This study provides insight into the pathways involved in anti-glaucoma drug transport, contributing to the optimization of drug design for improved therapeutic outcomes.
Low-concentration atropine is used for myopia control in children, but existing intraocular drug delivery models based on adult ocular geometry and physiological parameters may not accurately predict age-dependent drug transport in pediatric eyes. In this study, three-dimensional pediatric ocular drug transport models for children aged 4–7 and 8–12 years are established, incorporating age-dependent ocular geometries and physiological parameters to investigate the effects of age and dosing timing on intraocular heat transfer, biofluid flow, and atropine transport following topical administration. The results show that pediatric eyes exhibit lower temperature gradients in the anterior segment and lower peak aqueous humor and vitreous humor velocities than adult eyes, with the 4–7-year-old group exhibiting 9.95% and 13.20% lower peak atropine concentrations in the retina and choroid, respectively, but a 9.10% higher iris concentration than adults. Compared with nighttime dosing, daytime dosing increases the peak atropine concentrations in the retina and choroid by 18.98% and 18.02%, respectively. Under nighttime dosing, administration approximately 2 h before bedtime achieves target tissue concentrations comparable to those obtained with daytime dosing. These findings demonstrate the value of pediatric-specific ocular models incorporating age-dependent biological fluid dynamics, combined with optimized dosing timing, for predicting intraocular drug transport and improving atropine treatment strategies.